- Home
- ALPS vs ACET Comparison
ALPS vs ACET Comparison
Compare ALPS & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALPS | ACET |
|---|---|---|
| Founded | 2017 | 1947 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.5M | 79.9M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | ALPS | ACET |
|---|---|---|
| Price | $0.50 | $8.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $48.33 |
| AVG Volume (30 Days) | 61.4K | ★ 77.4K |
| Earning Date | 07-24-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.45 | $0.46 |
| 52 Week High | $1.72 | $9.47 |
Technical Indicators
Market Signals| Indicator | ALPS | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 32.01 | 46.22 |
| Support Level | N/A | $7.78 |
| Resistance Level | $0.77 | $8.68 |
| Average True Range (ATR) | 0.04 | 0.51 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 18.59 | 15.96 |
Price Performance
Historical ComparisonAbout ALPS ALPS Group Inc Ordinary Share
ALPS Group Inc is a fully integrated platform encompassing biotechnology research, medical, and wellness services specializing in predictive, precision and preventive health management. It aims to provide its clientele with access to DNA and mRNA sequencing, cellular therapy, as well as wellness and anti-aging products and services.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).